Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000031.xml
Klin Monbl Augenheilkd 2021; 238(04): 454-457
DOI: 10.1055/a-1384-1056
DOI: 10.1055/a-1384-1056
Der interessante Fall
Persistent Remnants of Dexamethasone Intravitreal Implant Over 24 Months in a Patient Suffering from Anterior and Intermediate Uveitis Associated with Macular Edema
Persistente Reste des intravitrealen Dexamethason-Implantats nach 24 Monaten bei einem Patienten mit Vorder- und Mittelstufe einer Uveitis, im Zusammenhang mit einem Makulaödem
Introduction
Several retinal diseases, including diabetic retinopathy, retinal vein occlusion, uveitis, wet age-related macular degeneration, complicated or uncomplicated ophthalmic surgery, and invasive treatment such as radiotherapy for ocular malignancy could be responsible for macular edema (ME), which is nowadays considered a leading cause of vision loss. It has been proven that chronic ME is associated with visual deterioration [1], [2], [3], [4]. In order to prevent irreversible visual deterioration and other complications, ME is an indication for treatment with corticosteroids, laser photocoagulation, and anti-vascular endothelial growth factor (anti-VEGF) [5].
Publication History
Received: 24 September 2020
Accepted: 29 January 2021
Article published online:
30 April 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
References
- 1 Yoon YH, Boyer DS, Maturi RK. et al. Natural history of diabetic macular edema and factors predicting outcomes in sham-treated patients (MEAD study). Graefes Arch Clin Exp Ophthalmol 2019; 257: 2639-2653 doi:10.1007/s00417-019-04464-2
- 2 Haller JA, Bandello F, Belfort jr. R. et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134-1146.e3 doi:10.1016/j.ophtha.2010.03.032
- 3 Longo A, Reibaldi M, Uva MG. et al. Acute serous macular detachment and edema after uncomplicated phacoemulsification: A case series. Can J Ophthalmol 2015; 50: 476-479 doi:10.1016/j.jcjo.2015.08.005
- 4 Russo A, Avitabile T, Uva M. et al. Radiation Macular Edema after Ru-106 Plaque Brachytherapy for Choroidal Melanoma Resolved by an Intravitreal Dexamethasone 0.7-mg Implant. Case Rep Ophthalmol 2012; 3: 71-76 doi:10.1159/000337144
- 5 Ceravolo I, Oliverio GW, Alibrandi A. et al. The Application of Structural Retinal Biomarkers to Evaluate the Effect of Intravitreal Ranibizumab and Dexamethasone Intravitreal Implant on Treatment of Diabetic Macular Edema. Diagnostics (Basel) 2020; 10: 413 doi:10.3390/diagnostics10060413
- 6 Augustin AJ, Kuppermann BD, Lanzetta P. et al. Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study. BMC Ophthalmol 2015; 15: 150 doi:10.1186/s12886-015-0148-2
- 7 Boyer DS, Yoon YH, Belfort jr. R. et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121: 1904-1914 doi:10.1016/j.ophtha.2014.04.024
- 8 Haller JA, Bandello F, Belfort jr. R. et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118: 2453-2460 doi:10.1016/j.ophtha.2011.05.014
- 9 Yalcinbayir O, Caliskan E. Ucan Gunduz G et al. Efficacy of Dexamethasone Implants in Uveitic Macular Edema in Cases with Behçet Disease. Ophthalmologica 2019; 241: 190-194 doi:10.1159/000490674
- 10 Lowder C, Belfort jr. R, Lightman S. et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129: 545-553 doi:10.1001/archophthalmol.2010.339
- 11 U.S. Food and Drug Administration (FDA). Drug Approval Package. Ozurdex (dexamethasone intravitreal implant). Accessed March 29, 2021 at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022315_ozurdex_toc.cfm
- 12 Chang-Lin JE, Attar M, Acheampong AA. et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011; 52: 80-86 doi:10.1167/iovs.10-5285
- 13 Lightman S, Belfort jr. R, Naik RK. et al. Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis. Invest Ophthalmol Vis Sci 2013; 54: 4864-4870 doi:10.1167/iovs.12-10981
- 14 Mazzarella S, Mateo C, Freixes S. et al. Effect of intravitreal injection of dexamethasone 0.7 mg (Ozurdex®) on intraocular pressure in patients with macular edema. Ophthalmic Res 2015; 54: 143-149 doi:10.1159/000438759
- 15 Maturi RK, Pollack A, Uy HS. et al. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD study. Retina 2016; 36: 1143-1152 doi:10.1097/iae.0000000000001004
- 16 Kim JT, Lee SH, Choi SU. Persistent remnants of dexamethasone intravitreal implant (Ozurdex). Retina 2020; 40: 2226-2231 doi:10.1097/iae.0000000000002778
- 17 Gillies MC, Simpson JM, Gaston C. et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology 2009; 116: 2182-2187 doi:10.1016/j.ophtha.2009.04.049
- 18 Ip MS, Gottlieb JL, Kahana A. et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch Ophthalmol 2004; 122: 1131-1136 doi:10.1001/archopht.122.8.1131
- 19 Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004; 111: 2044-2049 doi:10.1016/j.ophtha.2004.05.025
- 20 Sarraf D, Vyas N, Jain A. et al. Triamcinolone-associated crystalline maculopathy. Arch Ophthalmol 2010; 128: 685-690 doi:10.1001/archophthalmol.2010.109
- 21 Zarifa R, Shaikh S, Kester E. Peristence of triamcinolone crystals after intra-vitreal injection: benign crystalline hyaloidopathy. Indian J Ophthalmol 2013; 61: 182-183 doi:10.4103/0301-4738.112166
- 22 Lee SS, Hughes P, Ross AD. et al. Biodegradable implants for sustained drug release in the eye. Pharm Res 2010; 27: 2043-2053 doi:10.1007/s11095-010-0159-x
- 23 Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel) 2011; 3: 1377-1397 doi:10.3390/polym3031377
- 24 Yasukawa T, Ogura Y, Kimura H. et al. Drug delivery from ocular implants. Expert Opin Drug Deliv 2006; 3: 261-273 doi:10.1517/17425247.3.2.261
- 25 Reibaldi M, Russo A, Zagari M. et al. Resolution of Persistent Cystoid Macular Edema due to Central Retinal Vein Occlusion in a Vitrectomized Eye following Intravitreal Implant of Dexamethasone 0.7 mg. Case Rep Ophthalmol 2012; 3: 30-34 doi:10.1159/000336273
- 26 Boyer DS, Faber D, Gupta S. et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011; 31: 915-923 doi:10.1097/IAE.0b013e318206d18c